MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling
Qingfeng NiDepartment of General Surgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, PR ChinaYan ZhangDepartment of Chemotherapy, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, PR ChinaRan TaoDepartment of General Surgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, PR ChinaXiaolong LiDepartment of General Surgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, PR ChinaJianwei ZhuDepartment of General Surgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, PR China
2021en
ABI
Annotatsiya
experiments illustrated that miR-95-3p can effectively promote invasion, migration and tumorigenic capacity, respectively, of DDP-resistant GC cells. Subsequently, results from dual luciferase assay and qRT-PCR collectively indicated that EMP1 is a target of miR-95-3p with inhibitory function through suppression of the EMT process and drug-resistance proteins. Furthermore, PI3K/AKT was identified as a downstream pathway of miR-95-3p, which promotes DDP resistance in GC. In summary, miR-95-3p helped develop DDP-resistance through down-regulation of EMP1 and increasing phosphorylation of the PI3K/Akt pathway in GC.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba